 CAMBRIDGE, Mass., Jan. 18, 2022 PRNewswire -- Leap Therapeutics, Inc. Nasdaq:LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leaps anti-Dickkopf-1 DKK1 antibody, DKN-01, in combination with tislelizumab, BeiGenes anti-PD-1 antibody, in patients with gastric or gastroesophageal junction cancer GGEJ, at the American Society of Clinical Oncology ASCO Gastrointestinal GI Cancers Symposium being held on January 20-22, 2022. 